Perfluoro-n-octane as a postoperative vitreoretinal tamponade in the management of giant retinal tears

Retina

Volumn 25, Issue 7, 2005, Pages 897-901

  Rofail, Marc ^a,b   Lee, Lawrence R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b City Eye Centre   (Australia)

Author keywords

Giant retinal tear; Perfluoro n octane; Perfluorocarbon liquid; Retinal detachment; Vitrectomy

Indexed keywords

PERFLUOROOCTANE; SILICONE OIL;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; LASER; MALE; POSTOPERATIVE CARE; PROLIFERATIVE RETINOPATHY; RETINA DETACHMENT; RETINA TEAR; RETROSPECTIVE STUDY; SCLERA BUCKLING PROCEDURE; SUPINE POSITION; VISCOSITY; VITRECTOMY; VITREORETINAL TAMPONADE;

ADULT; DRAINAGE; FEMALE; FLUOROCARBONS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RETINAL DETACHMENT; RETINAL PERFORATIONS; TREATMENT OUTCOME; VITRECTOMY;

EID: 26844516542     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200510000-00013     Document Type: Article

References (27)

1. Wilkinson CP, Hengst TC. Current management of giant retinal tears and fellow eyes. In: Ryan SJ, ed. Retina. St. Louis: Mosby; 2001:2356-2370.
2. Scott IU, Murray T, Flynn HW, et al. Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane. Ophthalmology 2002;109:1828-1833.
3. Verstraeten T, Williams G, Chang S, et al. Lens-sparing vitrectomy with perfluorocarbon liquid for the primary treatment of giant retinal tears. Ophthalmology 1995;102:17-20.
4. Krieger AE, Lewis H. Management of giant retinal tears without scleral buckling. Use of radical dissection of the vitreous base and perfluoro-n-octane and intraocular tamponade. Ophthalmology 1992;99:491-497.
5. Kertes PJ, Wafapoor H, Peyman GA, Calixto N Jr, Thompson H. The management of giant retinal tears using perfluoroperhydrophenanthrene. A multicenter case series. Vitreon Collaborative Study Group. Ophthalmology 1997;104:1159-1165.
6. Hoffman ME, Sorr EM. Management of giant retinal tears without scleral buckling. Retina 1986;6:197-204.
7. Michels RG, Wilkinson CP, Rice TA. Retinal Detachment. St. Louis: Mosby; 1990:638-669.
8. Cairns JD, Campbell WG. Vitrectomy techniques in the management of giant retinal tears: a flexible approach. Aust N Z J Ophthalmol 1988;16:761-766.
9. Glaser BM. Treatment of giant retinal tears combined with proliferative vitreoretinopathy. Ophthalmology 1986;93:1193-1197.
10. Ambressin A, Wolfensberger TJ, Bovey EH. Management of giant retinal tears with vitrectomy, internal tamponade, and peripheral 360° retinal photocoagulation. Retina 2003;23:622-628.
11. Scott IU, Flynn HW, Murray T, Feuer WJ. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 2003;136:454-463.
12. Mathis A, Pagot V, Gazagne C, Malecaze F. Giant retinal tears. Surgical techniques and results using perfluorodecalin and silicone oil tamponade. Retina 1992;12:S7-S10.
13. Verma LK, Peyman GA, Wafapoor H, Greve MD, Millsap CM, Adile SL. An analysis of posterior segment complications using the perfluorocarbon perfluoroperhydrophenanthrene (Vitreon). Vitreon Collaborative Study. Ophthalmic Surg 1995;26:29-33.
14. Millsap CM, Peyman GA, Mehta NJ, et al. Perfluoroperhydrophenanthrene (Vitreon) in the management of giant retinal tears: results of a collaborative study. Ophthalmic Surg 1993;24:759-762.
15. Bottoni F, Bailo G, Arpa P, Prussiani A, Monticelli M, de Molfetta V. Management of giant retinal tears using perfluorodecalin as a postoperative short-term vitreoretinal tamponade: a long-term follow-up study. Ophthalmic Surg 1994; 25:365-373.
16. Campochiaro PA, Kaden IH, Vidaurri-Leal J. Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol 1985;103:434-436.
17. Machemer R, van Horn D, Aaberg TM. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol 1987;85:181-191.
18. Yoshizumi MO, Krieger AE, Sharp DM. Risk factors associated with development of massive preretinal proliferation. In: Ryan SJ, ed. Retinal Diseases. New York: Grune & Stratton; 1985:428-437.
19. Bishara SA, Buzney SM. Dispersion of retinal pigment epithelium from experimental retinal holes. Arch Ophthalmol 1981;229:195-199.
20. Lambrou FH, Bourke JM, Aaberg TM. Effect of silicone oil on traction retinal detachment. Arch Ophthalmol 1987;105:1269-1272.
21. Chang S, Sparrow J, Iwamoto T, et al. Experimental studies of tolerance to intravitreal perfluoro-n-octane liquid. Retina 1991;11:367-374.
22. Singh J, Ramesh K, Wharton SB, Cormack G, Chawla HB. Perfluorodecalin- induced intravitreal inflammation. Retina 2001;21:247-251.
23. Scott IU, Murray TG, Flynn HW Jr, Smiddy WE, Feuer WJ, Schiffman JC. Outcomes and complications associated with perfluoro-n-octane and perfluoroperhydrophenanthrene in complex retinal detachment repair. Ophthalmology 2000;107:860-865.
24. Liang C, Peyman GA. Tolerance of extended-term vitreous replacement with perfluoro-n-octane and perfluoroperhydrophenanthrene mixture. Retina 1999;19:230-237.
25. Lee GA, Finnegan SJ, Bourke BD. Subretinal perfluorodecalin toxicity. Aust N Z J Ophthalmol 1998;26:57-60.
26. Stolba U, Krepla K, Pflug R, et al. Experimental vitreous and aqueous replacement with perfluorophenanthrene. Retina 1997;17:146-153.
27. Elsing SH, Fekrat S, Green WR, Chang S, Wajer SD, Haller J. Clinicopathologic findings in eyes with retained perfluoro-n-octane liquid. Ophthalmology 2001;108:45-48.